Drug Profile
AVI 4020
Alternative Names: AVI-4020Latest Information Update: 02 Jul 2009
Price :
$50
*
At a glance
- Originator AVI BioPharma
- Class Antivirals
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued West Nile virus infections
Most Recent Events
- 03 Mar 2005 AVI 4020 is available for licensing worldwide for the treatment of West Nile Virus infections (http://www.avibio.com)
- 02 Sep 2004 Phase-I/II clinical trials in West Nile virus infections treatment in USA (unspecified route)
- 31 May 2004 Data presented at the 17th International Conference on Antiviral Research (ICAR-2004) have been added to the pharmacokinetics section